SCHEMBL6357846

SCHEMBL6357846

O=C(NCc1ccccc1OCc1ccccc1)c1cccc(Cl)c1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGMS2 Q8NHU3 3/20 0.61
PLA2G1B P04054 1/20 0.56
ATG4B Q9Y4P1 1/20 0.56
L3MBTL1 Q9Y468 3/20 0.55
LMNA P02545 3/20 0.55
MAPT P10636 2/20 0.55
MAPK8 P45983 2/20 0.55
ALDH1A1 P00352 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
HPGD P15428 3/20 0.55
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
TMEM97 Q5BJF2 1/20 0.49
SIGMAR1 Q99720 1/20 0.49
HTT P42858 2/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6356922 0.89 LMNA (0.57) SGMS2PLA2G1BATG4BL3MBTL1LMNA
SCHEMBL6354409 0.89 NPC1 (0.56) SGMS2PLA2G1BATG4BL3MBTL1LMNA
SCHEMBL6356674 0.89 KMT2A (0.57) SGMS2L3MBTL1LMNAMAPTALDH1A1
SCHEMBL6361006 0.88 L3MBTL1 (0.58) SGMS2PLA2G1BATG4BL3MBTL1LMNA
SCHEMBL6355252 0.88 SGMS2 (0.61) SGMS2L3MBTL1LMNAMAPTMAPK8
SCHEMBL6355643 0.87 HPGD (0.54) SGMS2PLA2G1BATG4BL3MBTL1LMNA
SCHEMBL6355280 0.85 LMNA (0.55) SGMS2PLA2G1BATG4BLMNAMAPT
SCHEMBL6354502 0.83 KMT2A (0.54) SGMS2LMNAMAPTALDH1A1TDP1
SCHEMBL6356156 0.83 ALDH1A1 (0.75) L3MBTL1LMNAMAPTMAPK8ALDH1A1
SCHEMBL6355111 0.83 ALDH1A1 (0.58) SGMS2L3MBTL1LMNAMAPTMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 SGMS2 3588/4885PLA2G1B 4010/4885ATG4B 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.